Pieper Steven 4

What Happened

• Steven Pieper, Chief Financial Officer of Xeris Biopharma, received equity awards and had shares withheld to satisfy tax-withholding obligations. On Jan 30, 2026 he was granted 154,986 restricted stock units (RSUs) and 207,207 derivative stock options (both $0 exercise price reported as grants). On Jan 31, 2026 a total of 205,534 shares were withheld/disposed at $7.36 per share to cover taxes, generating proceeds of $1,512,730 (111,765 @ $7.36 = $822,590; 66,450 @ $7.36 = $489,072; 27,319 @ $7.36 = $201,068).

Key Details

• Transaction dates: Jan 30, 2026 (grants); Jan 31, 2026 (share withholding/disposition).
• Prices/values: Withheld shares disposed at $7.36 each; total withholding value = $1,512,730. Grants reported at $0.00 (standard for awards).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes:
  • RSUs (F1): Each RSU represents a right to one share; RSUs vest in equal annual installments over three years, subject to continued employment.
  • Withholding (F2): The 205,534 shares were withheld by the issuer to satisfy income tax and withholding obligations in connection with the net settlement of RSUs vested as of Jan 31, 2026.
  • Options (F3): Stock options were granted and vest in equal annual installments over three years, subject to continued service.
• Filing: Report filed Feb 2, 2026, reporting Jan 30–31, 2026 transactions.

Context

• The disposals were tax-withholding transactions (code F), a routine administrative action when RSUs vest and do not necessarily signal a voluntary sale or change in insider sentiment. The grants (RSUs and options) are subject to multi-year vesting schedules; the options were not exercised and the RSUs were net-settled (shares withheld to cover taxes).